Supernus Pharmaceuticals Plans Third Quarter Earnings Call
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a leading biopharmaceutical company, is excited to share details about their upcoming conference call to discuss financial results for the third quarter of 2024. This event is set to take place shortly after the market closes, scheduled for November 4, 2024.
Overview of the Earnings Call
During this critical call, Jack Khattar, the President and CEO, along with Tim Dec, the Senior Vice President and CFO, will present key business results and financial performance. They will also offer insights into the company’s progress in the CNS sector, including recent advancements and product developments.
How to Participate in the Call
Participants can tune in to the call at 4:30 p.m. ET on the specified date. People interested in joining the call are encouraged to pre-register in advance, allowing them to receive a unique dial-in number along with a personalized conference code. It’s advisable to log in at least 15 minutes before the call starts to ensure a smooth connection.
Webcast Accessibility
A live webcast of the earnings call will be available, providing access for those who prefer an online format. After the event, a replay will also be accessible on the company’s Investor Relations website for anyone who cannot attend the live session. The recorded version will be available for 60 days, allowing ample time for viewing.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is dedicated to innovating treatments for central nervous system diseases. Their robust portfolio includes treatments for conditions such as epilepsy, migraines, ADHD, and more including hypomobility in Parkinson’s disease.
Current Pipeline and Future Outlook
In addition to established treatments, Supernus is actively working on new candidates aimed at tackling a range of CNS disorders. This includes exploring advancements in areas like depression and the ongoing management of Parkinson's disease. Their commitment to research and development marks them as a prominent player in the biopharmaceutical space.
Contact Information
For questions and further inquiries, interested parties can reach out to:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
For investor relations, contact:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Frequently Asked Questions
When will Supernus Pharmaceuticals hold their Q3 earnings call?
The Q3 earnings call is scheduled for November 4, 2024, at 4:30 p.m. ET.
Who will present the financial results during the call?
Jack Khattar, the President and CEO, and Tim Dec, Senior Vice President and CFO, will present the results.
Where can I access the earnings call live?
The earnings call will be available via a live webcast on the Supernus Investor Relations website.
How can I pre-register for the earnings call?
Participants can pre-register through the provided link on the company’s Investor Relations site prior to the call.
What is the focus of Supernus Pharmaceuticals?
Supernus Pharmaceuticals is focused on developing and commercializing products for treating central nervous system diseases.